Non-invasive characterization of human soft tissue sarcoma response to radiation therapy

人类软组织肉瘤对放射治疗反应的非侵入性表征

基本信息

  • 批准号:
    10448722
  • 负责人:
  • 金额:
    $ 26.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-15 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Everett Moding, MD, PhD is an Assistant Professor of Radiation Oncology at Stanford University School of Medicine. His long-term goal is to use his combined expertise in clinical and research medicine to make important discoveries in radiation and cancer biology that lead to better treatments for patients with sarcomas. He hopes to develop a translational research program using analysis of human tumor and blood samples to identify critical mediators of radiation resistance that can be validated in preclinical models and leveraged to enhance the efficacy of radiation therapy. The goal of this career development award is to provide support and mentorship to enable Dr. Moding to develop a successful independent research program. The proposal will be carried out under the mentorship of physician scientists Maximilian Diehn, MD, PhD, an expert in genomicsbased biomarkers, Ash Alizadeh, MD, PhD, an expert in tumor immunology and transcriptomic analysis tools, and David Kirsch, MD, PhD, a leader in radiation biology and mouse models. The training plan incorporates formal coursework, seminars, conferences, and programs along with informal hands-on and practical activities to expand Dr. Moding’s knowledge and expertise in 1) computational and systems biology, 2) tumor immunology and sarcoma biology, and 3) laboratory management, mentoring, and grantsmanship. Soft tissue sarcomas (STS) are a diverse group of mesenchymal tumors primarily managed with surgery and radiation therapy for localized disease. Although half of patients with high risk STS develop metastatic disease after initial therapy, there are no biomarkers to identify patients at risk of relapse. In addition, up to two-thirds of patients with STS develop local recurrences after radiation therapy alone, but the underlying genetic alterations that mediate radiation resistance are unknown. By analyzing tumor and peripheral blood samples collected from 102 patients enrolled on the SU2C-SARC032 phase II clinical trial, this research proposal aims to 1) establish personalized circulating tumor DNA analysis as a biomarker in patients with STS, 2) build a prognostic model integrating tumor microenvironment profiling, circulating tumor DNA analysis, and traditional risk factors to improve prediction of patient outcomes, and 3) use circulating tumor DNA analysis and tumor sequencing to identify genetic alterations that mediate the response of sarcomas to radiation therapy for rapid functional validation in novel preclinical platforms. This proposal will lay the groundwork for future prospective randomized trials using circulating tumor DNA analysis and tumor genomics to enable personalized treatment approaches in patients with STSs that improve the probability of tumor eradication while minimizing treatment-related toxicity.
项目概要/摘要 Everett Moding 博士是斯坦福大学放射肿瘤学助理教授 药品。他的长期目标是利用他在临床和研究医学方面的综合专业知识,做出重要的贡献 放射和癌症生物学方面的发现为肉瘤患者提供了更好的治疗方法。他希望 通过分析人类肿瘤和血液样本来开发转化研究计划,以确定关键的 抗辐射介质,可以在临床前模型中进行验证并用于增强 放射治疗的疗效。 该职业发展奖的目标是提供支持和指导,使莫丁博士能够 制定成功的独立研究计划。该提案将在以下人员的指导下进行: 医师科学家 Maximilian Diehn,医学博士,哲学博士,基于基因组学的生物标志物专家,Ash Alizadeh,医学博士, 博士,肿瘤免疫学和转录组分析工具专家,David Kirsch 博士,医学博士,博士,肿瘤免疫学和转录组分析工具领域的领导者 辐射生物学和小鼠模型。培训计划包括正式课程、研讨会、会议、 和计划以及非正式的实践和实践活动,以扩展莫丁博士的知识和 1) 计算和系统生物学、2) 肿瘤免疫学和肉瘤生物学、3) 实验室专业知识 管理、指导和资助。 软组织肉瘤 (STS) 是一组多样化的间叶性肿瘤,主要通过手术和 针对局部疾病的放射治疗。尽管半数高危 STS 患者会发展为转移性疾病 初始治疗后,没有生物标志物可以识别有复发风险的患者。此外,高达三分之二的 STS 患者在单独放疗后会出现局部复发,但潜在的基因改变 介导辐射抗性的因素尚不清楚。通过分析从以下组织收集的肿瘤和外周血样本 SU2C-SARC032 II 期临床试验入组了 102 名患者,本研究提案旨在 1) 建立 个性化循环肿瘤 DNA 分析作为 STS 患者的生物标志物,2) 建立预后模型 整合肿瘤微环境分析、循环肿瘤 DNA 分析和传统危险因素 改善对患者结果的预测,3) 使用循环肿瘤 DNA 分析和肿瘤测序来 识别介导肉瘤对放射治疗快速功能反应的基因改变 在新颖的临床前平台中进行验证。该提案将为未来的前瞻性随机化奠定基础 使用循环肿瘤 DNA 分析和肿瘤基因组学的试验,以实现个性化治疗方法 患有 STS 的患者可以提高肿瘤根除的可能性,同时最大限度地减少治疗相关的毒性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Everett James Moding其他文献

Everett James Moding的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Everett James Moding', 18)}}的其他基金

Non-invasive characterization of human soft tissue sarcoma response to radiation therapy
人类软组织肉瘤对放射治疗反应的非侵入性表征
  • 批准号:
    10684135
  • 财政年份:
    2022
  • 资助金额:
    $ 26.22万
  • 项目类别:
Defining the cellular target of radiotherapy in primary mouse models of cancer
在原代小鼠癌症模型中定义放疗的细胞靶点
  • 批准号:
    8526641
  • 财政年份:
    2013
  • 资助金额:
    $ 26.22万
  • 项目类别:
Defining the cellular target of radiotherapy in primary mouse models of cancer
在原代小鼠癌症模型中定义放疗的细胞靶点
  • 批准号:
    8641563
  • 财政年份:
    2013
  • 资助金额:
    $ 26.22万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 26.22万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 26.22万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 26.22万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 26.22万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 26.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 26.22万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 26.22万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 26.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 26.22万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 26.22万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了